For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Agouron Pharmaceuticals, Inc.

USPTO Granted Patents = 174

CIPO Patents = 1

Trademarks = 3

Forward Citations = 2,186

Loading Chart...

Loading Chart...

330 inventors (with patents filed for the assignee):

Siegfried Heinz Reich (36 out of 50 patents)

Michael D Varney (33 out of 33 patents)

Cynthia Louise Palmer (26 out of 38 patents)

4. John Howard Tatlock (20 out of 30 patents)

5. Steven Lee Bender (19 out of 26 patents)

6. Stephen Evan Webber (17 out of 54 patents)

7. William H Romines (17 out of 17 patents)

8. Vincent J Kalish (16 out of 16 patents)

9. Peter Scott Dragovich (14 out of 54 patents)

10. Michael J Rodriguez (14 out of 35 patents)

11. Robert Steven Kania (12 out of 39 patents)

12. Thomas Jay Prins (12 out of 13 patents)

13. Michael J Melnick (12 out of 13 patents)

14. Ru Zhou (11 out of 16 patents)

15. Theodore Otto Johnson, Jr (11 out of 13 patents)

Core Competencies:

Protein Kinase Inhibitors

VEGF-R Inhibitors

P-cadherin Antibodies

Poly(ADP-ribose) Polymerases

HIV Protease Inhibitors

Hepatitis C Virus Inhibitors

Indazole Compounds

Thienopyridine Derivatives

Benzofused Heterocyclic Compounds

Pyrrolopyrazole Derivatives

Antipicornaviral Compounds

Tricyclic Compounds

174 patents: Sort by Forward Citations

1. 8785632 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2014-07-22),

2. 8530652 - Pyrrolopyrazoles, potent kinase inhibitors (2013-09-10),

3. 8067591 - Pyrrolopyrazole, potent kinase inhibitors (2011-11-29),

4. 7928226 - Salts and polymorphs of a VEGF-R inhibitor (2011-04-19),

5. 7928214 - P-cadherin antibodies (2011-04-19),

6. 7923457 - Quinoline derivatives (2011-04-12),

7. 7858643 - Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors (2010-12-28),

8. 7807159 - Antibodies to myostatin (2010-10-05),

9. 7465842 - Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates (2008-12-16),

10. 7462713 - Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy (2008-12-09),

11. 7462634 - N-(pyridin-2-yl)-sulfonamide derivatives (2008-12-09),

12. 7452537 - P-cadherin antibodies (2008-11-18),

13. 7429578 - Tricyclic inhibitors of poly(ADP-ribose) polymerases (2008-09-30),

14. 7381824 - Quinoline derivatives (2008-06-03),

15. 7323562 - Method of preparing poly(ADP-ribose) polymerases inhibitors (2008-01-29),

Agouron Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. They specialized in creating small molecule drugs to treat cancer and viral infections. Agouron was known for its groundbreaking research in protein structure determination and structure-based drug design. The company was founded in 1984 and became a subsidiary of Pfizer in 2000.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

174 Patents

#32 in San Diego, CA

#514 in California

#2,231 in US

#4,645 in the World

San Diego, CA, United States of America

Agouron Pharmaceuticals, Inc.

Forward Citations = 2,186

330 inventors:

Siegfried Heinz Reich (36 out of 50 patents)

Michael D Varney (33 out of 33 patents)

Cynthia Louise Palmer (26 out of 38 patents)

4. John Howard Tatlock (20 out of 30 patents)

5. Steven Lee Bender (19 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…